

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版者名	出版地	出版年	ページ
正木尚彦	第 章 肝疾患診療に関する病診連携 1. 肝疾患診療連携拠点病院ならびに肝疾患診療連携ネットワーク. 第 章 肝疾患診療に関連する法律、制度 2. 肝炎対策基本法、3. 肝炎治療特別促進事業（医療費助成制度）	日本肝臓学会	肝臓専門医テキスト	南江堂	東京	2013	pp460-464、pp472-473、pp474-479
正木尚彦	急性肝炎サーベイランスの現状	山本和秀監修、考田雅彦・能祖一裕編集	わが国における急性肝炎の現状 全国調査 2008-2011	中外医学社	東京	2012	pp20-25
坂本穂、榎本信幸	慢性肝炎・肝硬変（C型）	一瀬雅夫、岡政志、持田智	治療過程で一目でわかる消化器薬物療法 STEP 1・2・3	メジカルビュー社	東京	2013	174-178
辰巳明久、坂本穂、榎本信幸	メタボ肝癌とファイブロスキャン	小俣政男	メタボ肝癌	アークメディア	東京	2013	163-168
坂本穂、榎本信幸	C型肝炎	浅香正博、菅野健太郎、千葉勉	カラー版消化器病学 基礎と臨床	西村書店	東京	2013	1177-1188
坂本穂、榎本信幸	ウイルス肝炎治療薬、薬物治療と薬理メカニズム	門脇孝・永井良三	カラー版内科学	西村書店	東京	2012	246-249
坂本穂、榎本信幸	[C型肝炎の治療 初回治療]について	泉並木	ガイドライン/ガイドランス 慢性肝炎 こう診る・こう考える	日本医事新報社	東京	2011	20-25
坂本穂、榎本信幸	硬変化した慢性肝炎の治療をどう考えるか	井廻道夫	消化器 Book 04 これでわかる! 慢性肝炎の治療戦略 肝癌を防ぐためのマネジメント	羊土社	東京	2011	106-112
坂本穂、榎本信幸	HCVのNS5A遺伝子変異（ISDR・IRRDR）とインターフェロン治療反応性		新時代のウイルス性肝炎学	日本臨床社	大阪	2011	234-238
三浦美香、前川伸哉、門倉信、末木良太、小馬瀬一樹、進藤浩子、進藤邦明、雨宮史武、中山康弘、植竹智義、井上泰輔、坂本穂、榎本信幸	肝発癌に関連するC型肝炎ウイルス遺伝子領域とIL28B SNPの解析、分子消化器病研究会	小俣政男	第18回浜名湖シンポジウム記録集 消化器疾患と幹細胞;その基礎と臨床	アークメディア	東京	2011	171-177
酒井明人、荒井邦明、金子周一	肝臓癌の予防とサーベイランス	浅香正博	G.I. Research	先端医学社	東京	2011	334-341
酒井明人	石川県の肝癌撲滅戦略	浅香正博	The GI Forefront	メディカルレビュー社	東京	2012	119-121
渡邊綱正、田中靖人	HCV感染とIL28B	小俣政男	2012-2013 肝疾患 Review	日本メディカルセンター	東京	2012	96-101
井上和明、渡邊綱正	急性肝炎におけるEBVとCMV	山本和秀	わが国における急性肝炎の現状 全国調査 2008-2011	中外医学社	東京	2012	46-51
渡邊綱正、杉浦互、田中靖人	HIV合併例を含めたB型急性肝炎症例の検討	山本和秀	わが国における急性肝炎の現状 全国調査 2008-2011	中外医学社	東京	2012	76-79

渡邊綱正	肝炎ウイルス	吉開泰信, 西山幸廣	レピンソン 微生物学・免疫学 [原書 11 版]	丸善出版	東京	2012	295-304
渡邊綱正	慢性肝炎・肝硬変	日本臨床検査医学会ガイドライン作成委員会	臨床検査のガイドライン JSLM2012 検査値アプローチ / 症候 / 疾患	日本臨床検査医学会	東京	2012	279-283
吉岡健太郎	α ₁ -アンチトリプシン欠乏症	矢崎義雄	内科学 (第 10 版)	朝倉書店	東京	2013	69-70
吉岡健太郎	肝腫大	矢崎義雄	内科学 (第 10 版)	朝倉書店	東京	2013	1162-1163
吉岡健太郎	Wilson 病	小俣政男、千葉勉	専門医のための消化器病学第 2 版	医学書院	東京	2013	399-401
吉岡健太郎	ヘモクロマトーシス	小俣政男、千葉勉	専門医のための消化器病学第 2 版	医学書院	東京	2013	401-403
吉岡健太郎, 橋本千樹, 西川徹	藤田保健衛生大学病院 肝胆膵内科・超音波センター	戸田剛太郎, 井廻道夫, 幕内雅敏, 白鳥恵子	先端医療シリーズ 42 消化器疾患の最新医療	先端医療技術研究所	東京	2011	450-453
伊藤清顕、溝上雅史	全国調査からみた B 型慢性肝炎の病態	佐田通夫 田中榮司 田中英夫 長尾由実子	コホート研究からみたウイルス性肝炎の解明	メディカルレビュー社	大阪府	2013	152-160
伊藤清顕、溝上雅史	【C 型肝炎個別化医療のための宿主因子、ウイルス因子】 C 型肝炎に対する PEG-IFN/RBV48 週および 72 週投与の治療効果に関連する IL28B および ITPA 遺伝子多型の解析		消化器内科	科学評論社	東京都	2012	222-227
伊藤清顕	治療効果予測因子のトピックス 宿主側因子 IL28B SNPs	芥田憲夫 斉藤聡 角田圭雄	最新! C 型肝炎治療薬の使いかた	診断と治療社	東京都	2012	68-70
伊藤清顕、溝上雅史	Genotype A による B 型急性肝炎の拡大とその特徴 B 型肝炎 最新治療コンセンサス 2012	溝上雅史	医学のあゆみ	医歯薬出版株式会社	東京都	2012	389-394
伊藤清顕、溝上雅史	ウイルス肝炎のすべて III 血液感染するウイルス肝炎 1. B 型肝炎 (2) HBV 遺伝子型と B 型急性肝炎		化学療法の領域増刊号	医薬ジャーナル社	大阪市	2012	104-1051
村田一素、伊藤清顕、溝上雅史	遺伝子多型は HCV 肝炎の病態、薬剤の効果にどう影響するのか	千葉勉	分子消化器病学	先端医学社	東京都	2011	227-232
伊藤清顕	B 型肝炎に影響を与える個体差	上野義之	肝胆膵	アークメディア	東京都	2011	897-902
伊藤清顕、斉藤紘昭、溝上雅史	C 型肝炎治療における IL28B の有用性と今後の問題 どの SNPs をどの測定法で測定すべきか	犬山シンポジウム記録刊行会	第 28 回 犬山シンポジウム記録集	メディカルトリビューン	東京都	2011	117-122
伊藤清顕、溝上雅史	SNP が決定する治療効果: IL28B および ITPA SNPs	坂本直哉	肝胆膵	アークメディア	東京都	2011	315-324
伊藤清顕、正木尚彦	B 型肝炎ウイルス再活性化	田尻久雄	臨床消化器内科	日本メディカルセンター	東京都	2011	369-373
正木尚彦、伊藤清顕、溝上雅史	HCV 治療の有効性と IL28B (インターフェロン)		感染炎症免疫	医薬の門社	東京都	2011	380-383
飯島尋子	画像検査を用いた新しい線維化診断法	西口修平 編	別冊医学のあゆみ 肝硬度 Update-肝硬変死の根絶をめざして	医歯薬出版	東京	2013	43-8
飯島尋子, 田中弘教		日本肝臓学会 編	肝臓専門医テキスト	南江堂	東京	2013	
田中弘教, 飯島尋子	実地での留意点・実地での留意点	高山忠利, 泉並木 編	診療ガイドラインに沿った肝臓治療の要点と盲	文光堂	東京	2013	26-8

			点 .				
飯島尋子	Sonazoid の特性 .	工藤正俊・國分茂博 編	EOB-MRI/Sonazoid 超音波による肝 癌の診断と治療 .	医学書院	東京	201 3	202-4
田中弘教, 飯島尋子	肝癌のスクリーニングや確定診断で造影エ コーはどのように使うのが効果的でしょう か? .	池田健次 編	肝癌診療 Q&A .	中外医学社	東京	201 3	48-50
飯島尋子, 山平正浩	エラストグラフィ・画像診断 .	竹井謙之・竹原徹 郎・持田智 編 .	Hepatology Practice 第 2 卷 NASH・アルコール 性肝障害の診療 を極める	文光堂	東京	201 3	141-5
相崎 英樹	HCV 感染と代謝異常 (脂質・エネルギー)	医歯薬出版株式会社	医学のあゆみ		東京	201 3	245;666-667
田中 純子、小山 富子、 相崎 英樹	C 型肝炎ウイルス(HCV)による感染	日本臨床ウイルス学 会	臨床とウイルス	日本臨床ウイルス 学会	神奈 川	201 2	28-35
相崎 英樹	HCV 粒子形成に関する脂肪滴周辺膜蛋白の 同定と機能解析					201 2	30-33
相崎 英樹	細胞生物学講座 C 型肝炎ウイルスの生活環		細胞	ニューサイエンス 社		201 2	419-422
相崎英樹、脇田隆字	HCV 感染における脂質代謝の変化とメタボロ ミクス解析	小俣政男	肝胆膵	アークメディア	東京	201 1	948-953
相崎英樹、鈴木哲朗、脇 田隆字	HCV 生活環における脂質の役割	井廻道夫	日本臨床	日本臨床社	大阪	201 1	59-63

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版 年
正木尚彦	ウイルス肝炎に関する国の対策事業、公費助 成や受診勧奨など . 特集 ウイルス肝炎の新 展開	診断と治療	101(9)	1375-1380	201 3
正木尚彦	肝炎をめぐる医療政策	医学のあゆみ	240(12)	997-999	201 2
正木尚彦	ウイルス肝炎検診と病診連携の重要性と進め かた	Medical Practice	28(8)	1453-1457	201 1
Kudo M	Advances in Liver Fibrosis Imaging and Hepatocellular Carcinoma: Update in 2013.	Oncology	84	1-2	201 3
Fujimoto K, Kato M, Kudo M, Yada N, Shiina T, Ueshima K, Yamada Y, Ishida T, Azuma M, Ymasaki M, Yamamoto K, Hayashi N, Takehara T	Novel image analysis method using ultrasound elastography for non-invasive evaluation of hepatic fibrosis in patients with chronic hepatitis C.	Oncology	84	3-12	201 3
Yada N, Morikawa H, Fujimoto K, Kato M, Kawada N, Kudo M	Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitis.	Oncology	84	13-20	201 3
Kudo M, Matsui O, Sakamoto M, Kitao A, Kim T, Ariizumi S, Ichikawa T, Kobayashi S, Imai Y, Izumi N, Fujinaga Y, Arie S	Role of gadolinium-ethoxybenzyl-diethylenetriamin e pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA MRI) in the management of hepatocellular carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan.	Oncology	84	21-27	201 3

Inoue T, <u>Kudo M</u> , Hatanaka K, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Ueshima k, Nishida N	Usefulness of contrast-enhanced ultrasonography to evaluate the post treatment responses of radiofrequency ablation for hepatocellular carcinoma; comparison with dynamic CT.	Oncology	84	51-57	2013
Minami Y, <u>Kudo M</u>	Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: US, CT and MRI.	Oncology	84	58-63	2013
Minata M, Harada K, <u>Kudo M</u> , Ikai I, Nishida N	The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection.	Oncology	84	75-81	2013
Nishida N, Arizumi T, Takita M, Nagai T, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Ida H, <u>Kudo M</u>	Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma.	Oncology	84	82-87	2013
Minata M, <u>Kudo M</u> , Harada K, Ikai I, Nishida N	Expression of E-cadherin and vascular endothelial growth factor in non-cancerous liver is associated with recurrence of HCC after curative resection.	Oncology	84	88-92	2013
Nishida N, <u>Kudo M</u>	Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma.	Oncology	84	93-97	2013
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, <u>Kudo M</u> , Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX	Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.	Ultrasound Med Biol	39	187-210	2013
Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, <u>Kudo M</u> , Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, for the Liver Cancer Study Group of Japan.	Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.	J Hepatol	58	724-729	2013
Sakurai T, <u>Kudo M</u> , Umemura A, He G, Elsharkawy AM, Seki E, Karin M	p38 α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.	Cancer Res	73	215-224	2013
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, <u>Kudo M</u> , Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen	Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and	Ultraschall Med	34	11-29	2013

MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX	ICUS.				
Watanabe T, Yamashita K, Sakurai T, <u>Kudo M</u> , Shiokawa M, Uza N, Kadoma Y, Uchida K, Okazaki K, Chiba T	Toll-like receptor activation in basophils contributes to the development of IgG4-related disease.	J Gastroenterol	48	247-253	201 3
Nagata Y, <u>Kudo M</u> , Nagai T, Watanabe T, Kawasaki M, Asakuma Y, Hagiwara S, Nishida N, Matsui S, Kashida H, Sakurai T	Heat shock protein 27 expression is inversely correlated with atrophic gastritis and intraepithelial neoplasia.	Digest Dis Sci	58	381-388	201 3
Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, <u>Kudo M</u> , Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Ceng AL	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).	Liver Int	33	327-337	201 3
Minami Y, <u>Kudo M</u>	Radiofrequency ablation of liver metastases from colorectal cancer: a literature review.	Gut Liver	7	1-6	201 3
Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa K, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Hidenori Toyoda, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, <u>Kudo M</u>	FGF3/FGF4 Amplification and Multiple lung Matastases in responders to sorafenib in hepatocellular carcinoma.	Hepatology	57	1407-1415	201 3
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwaru E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi K, Katsushima S, <u>Kudo M</u> , Takaguchi K, Hiasa Y, Chayama K, Yatsuhashi H, Oketani M, Kumada H	Inhibition of hepatocellular carcinoma by PegIFN α -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	J Gastroenterol	48	382-390	201 3

Takayasu K, Arii S, Sakamoto M, Matsuyama Y, <u>Kudo M</u> , Ichida T, Nakashima O, Matsui O, Izumi N, Ku Y, Kokudo N, Makuuchi M, Liver Cancer Study Group of Japan	Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm.	Liver Int	33	762-770	2013
Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, <u>Kudo M</u> , Mochizuki T	Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.	Radiology	266	480-490	2013
Hagiwara S, <u>Kudo M</u> , Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T, Yada Y, Nishida N	Impact of peginterferon Alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.	J Med Virol	85	987-95	2013
<u>Kudo M</u>	Early Hepatocellular Carcinoma: Definition and Diagnosis.	Liver Cancer	2(2)	69-72	2013
Matsui S, Kashida H, <u>Kudo M</u>	Senile systemic amyloidosis localized to the stomach.	Digest Endosc	25	468-469	2013
Mine H, Sakurai T, Kashida H, Matsui S, Nishida N, Nagai T, Hagiwara S, Watanabe T, <u>Kudo M</u>	Association of gankyrin and stemness factor expression in human colorectal cancer.	Dig Dis Sci	58	2337-2344	2013
Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, <u>Kudo M</u> , Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y	A randomized phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolization.	Eur J Cancer	49	2832-2840	2013
Takayama M, Matsui S, Kawasaki M, Asakuma Y, Sakurai T, Kashida H, <u>Kudo M</u>	Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers.	World J Gastroenterol	19	5706-5712	2013
<u>Kudo M</u>	[Preface] Chronic liver diseases and hepatocellular carcinoma: update in 2013.	Digest Dis	31	405-407	2013
Nishida N, Iwamura S, Ida H, Hagiwara S, Kagioka Y, Minami Y, Maetani Y, Itoh K, <u>Kudo M</u>	Clinical and histological features of different types of Budd-Chiari syndrome: A Comparison of 4 cases.	Digest Dis	31	408-414	2013
Yada N, <u>Kudo M</u> , Chung H, Watanabe T	Autoimmune hepatitis and immunoglobulin G4-associated autoimmune Hepatitis.	Digest Dis	31	415-420	2013
Sugimoto K, Kim SR, Shamy AE, Imoto S, Ando K, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Takashi H, Hotta H, Hayashi Y, <u>Kudo M</u>	Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance.	Digest Dis	31	421-425	2013

Kim SR, Shamy AE, Imoto S, Kim KI, Sugimoto K, Kim SK, Tanaka Y, Hatae T, Hasegawa Y, Fujinami A, Ohta M, Hotta H, <u>Kudo M</u>	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.	Digest Dis	31	426-433	201 3
Sugimoto K, Kim SR, Shamy AE, Imoto S, Fujioka H, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Hatae T, Hotta H, Hayashi Y, <u>Kudo M</u>	Outcome of double-filtration plasmapheresis plus IFN treatment in non-responders to pegylated IFN plus ribavirin combination therapy.	Digest Dis	31	434-439	201 3
Sakurai T, <u>Kudo M</u> , Watanabe T, Itoh K, Higashitsuji H, Arizumi T, Inoue T, Hagiwara S, Ueshima K, Nishida N, Fukumoto M, Fujita J	Hypothermia Protects against Fulminant Hepatitis in Mice by Reducing Reactive Oxygen Species Production.	Digest Dis	31	440-446	201 3
Nishida N, <u>Kudo M</u>	Oxidative stress and epigenetic instability in human hepatocarcinogenesis.	Digest Dis	31	447-453	201 3
Kim SK, Marusawa H, Eso Y, Chiba T, <u>Kudo M</u>	Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations.	Digest Dis	31	454-458	201 3
Nishida N, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, <u>Kudo M</u>	Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis.	Digest Dis	31	459-466	201 3
Tsuji N, Ishiguro S, Sasaki Y, <u>Kudo M</u>	CD-34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma.	Digest Dis	31	467-471	201 3
Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, <u>Kudo M</u>	Hypovascular hepatic nodules showing hypointense on the hepatobiliary phase image of Gd-EOB-DTPA enhanced MRI to develop a hyper-vascular hepatocellular carcinoma: a nationwide retrospective study on their Natural course and Risk factors.	Digest Dis	31	472-479	201 3
Minami Y, Hayaishi S, <u>Kudo M</u>	Radiofrequency ablation for hepatic malignancies: is the needle tract cauterization necessary for preventing iatrogenic bleeding?	Digest Dis	31	480-484	201 3
Makino Y, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Hori M, <u>Kudo M</u> , Murakami T	Usefulness of the extracted-overlay function in CT/MR-ultrasonography fusion imaging for radiofrequency ablation of hepatocellular carcinoma.	Digest Dis	31	485-489	201 3
<u>Kudo M</u> , Osaki Y, Matsunaga T, Kasugai H, Oka H, Seki T, the Osaka Liver Cancer Study Group	Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments.	Digest Dis	31	490-498	201 3

<u>Kudo M</u>	Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma?	Liver Cancer	2(3-4)	151-152	201 3
Sakurai T, <u>Kudo M</u>	Molecular link between liver fibrosis and hepatocellular carcinoma.	Liver Cancer	2(3-4)	365-366	201 3
<u>Kudo M</u> , Shiina T, Moriyasu F, Iijima H, Tateishi R, Yada N, Fujimoto K, Morikawa H, Hirooka M, Sumino Y, Kumada T	JSUM ultrasound elastography practice guidelines: liver.	J Med Ultrason	40	325-357	201 3
Kagawa Y, Okada M, Yagyu Y, Kumano S, Kanemitsu M, <u>Kudo M</u> , Murakami T	Optimal scan timing of hepatic arterial-phase imaging of hypervascular hepatocellular carcinoma determined by multiphasic fast CT imaging technique.	Acta Radiol	54	843-850	201 3
Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, <u>Kudo M</u> , Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K, the Liver Cancer Study Group of Japan	Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.	Brit J Cancer	109	1904-1907	201 3
Cheng AL, Kang YK, Lin DY, Park JW, <u>Kudo M</u> , Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Lowenthal SP, Lanzalone S, Yang L, Lechuga MJ, Raymond E, for the SUN1170 HCC Study Group	Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.	J Clin Oncol	10: 31	4067-4075	201 3
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Avina JR, <u>Kudo M</u> , Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL	Brivanib versus Sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase 3 BRISK-FL study.	J Clin Oncol	1: 31	3517-3524	201 3
Llovet JM, Decaens T, Raoul JL, Boucher E, <u>Kudo M</u> , Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc, JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park	Brivanib in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: or for whom sorafenib failed results from the randomized phase 3 BRISK-PS study.	J Clin Oncol	1: 31	3509-3516	201 3

JW					
Lencioni R, <u>Kudo M</u> , Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ	GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.	Int J Clin Pract		1-9	2013
Nishida N, <u>Kudo M</u> , Nishimura T, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Yokomichi N, Nagasaka T, Goel A	Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma.	Plos One	8(9)	e72312	2013
Minami Y, Okumura N, Yamamoto N, Tsuji N, Kono Y, <u>Kudo M</u>	Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases.	J Med Ultrason	28	15-19	2012
Kitano M, <u>Kudo M</u> , Yamao K, Takagi T, Sakamoto H, Komaki T, Kamata K, Imai H, Chiba Y, Okada M, Murakami T, Takeyama Y	Characterization of small solid tumors in the pancreas: The value of contrast-enhanced harmonic endoscopic ultrasonography.	Am J Gastroenterol	107	303-310	2012
Sakamoto H, Kimura H, Sekijima M, Matsumoto K, Arao T, Chikugo T, Yamada Y, Kitano M, Ito A, Takeyama Y, <u>Kudo M</u> , Nishio K	Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer.	Jpn J Clin Oncol	42	105-112	2012
Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, Abecassis M, Balabaud C, Barritt GJ, Belghiti J, Bhoori S, Bossuyt P, Breitenstein S, Broelsch C, Bruix J, Burra P, Burroughs A, Busuttil R, Charlton M, Cherqui D, Colombo ML, d'Albuquerque C, D'Alessandro A, de Santibanez EJ, Dufour F, Durand F, Dutkowsky P, Duvoux C, El-Serag H, Fan ST, Finn RS, Fisher R, Forner A, Freeman R, Fung J, Geier A,	Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.	Lancet Oncol	13	e11-22	2012

<p>Germani G, Gores G, Gouw AS, Grant D, Greig P, Gurusamy K, Hanto D, Heaton N, Heim M, Hemming A, Hippen B, Hisham A, Hubscher S, Ichida T, Kahn D, Kew M, Kita Y, Kiuchi T, Klintmalm GB, Kneteman N, Kojiro M, <u>Kudo M</u>, Langer B, Lee JM, Lee SG, Lencioni R, Lerut J, Lesurtel M, Livraghi T, Llovet JM, Lo CM, Lodge P, MacCaughan G, Madoff D, Majno P, Marcellin P, Marrero J, Mazzaferro V, Mergental H, Merle P, Miksad R, Mornex F, Mullhaupt B, Olthoff K, Paradis V, Perrier A, Pestalozzi B, Pomfret E, Poon R, Porte R, Greig P, Prasad KR, Raptis D, Roskams T, Rossi M, Samuel D, Schlitt H, Schwartz M, Sexton Dobby AM, Shaked A, Sherman M, Siegler M, Suh KS, Todo S, Toso C, Trevisani F, Trotter JJ, Veldecasas GJ, Vauthey N, Vilgrain V, Villamil F, Vonlanthen R, Wald C, Weber A, Wiesner R, Wright L, Yao F, Zheng SS, Zucman-Rossi J</p>					
<p>Minami Y, Kitai S, <u>Kudo M</u></p>	<p>Treatment response assessment of radiofrequency ablation for hepatocellular carcinoma: Usefulness of virtual CT sonography with magnetic navigation.</p>	<p>Eur J Radiol</p>	<p>81</p>	<p>e277-280</p>	<p>201 2</p>
<p>Watanabe T, Yamashita K, Fujikawa S, Sakurai T, <u>Kudo M</u>, Shiokawa M, Kodama Y, Uchida K, Okazaki K, Chiba T</p>	<p>Involvement activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis.</p>	<p>Arthritis Rheum</p>	<p>64</p>	<p>914-924</p>	<p>201 2</p>
<p>Takayasu K, Arie S, <u>Kudo M</u>, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M</p>	<p>Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.</p>	<p>J Hepatol</p>	<p>56</p>	<p>886-892</p>	<p>201 2</p>
<p><u>Kudo M</u>, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N,</p>	<p>Current status of hepatocellular carcinoma treatment in Japan: Case study and discussion-voting system.</p>	<p>Clin Drug Invest</p>	<p>32:suppl.2</p>	<p>37-51</p>	<p>201 2</p>

Matsui O					
<u>Kudo M</u>	Closing remarks.	Clin Drug Invest	32:suppl.2	52	201 2
Saito J, Kim SR, <u>Kuod M</u> , Imoto S, Ando K, Nakajima T, Fukuda K, Otono Y, Kim SK, Komaki T, Yano H, Nakashima O, Sugimoto K, Matsuoka T	Well-differentiated hepatocellular carcinoma detected as hypovascularity by only CT during hepatic arteriography.	Intern Med	51	885-890	201 2
Lencioni R, <u>Kudo M</u> , Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA	First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study.	Int J Clin Pract	66	675-683	201 2
Okada M, Ishii K, Numata K, Hyodo T, Kumano S, Kitano M, <u>Kudo M</u> , Murakami T	Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function ?	Hepatob Pancreatic Dis Int	11	307-313	201 2
<u>Kudo M</u>	Welcome to the first issue of Liver Cancer.	Liver Cancer	1(1)	1	201 2
Hagiwara S, <u>Kudo M</u> , Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T, Sakurai T	Activation of JNK and high expression level of CD133 predict a poor response to Sorafenib in hepatocellular carcinoma.	Brit J Cancer	106	1997-2003	201 2
Shiina T, Maki T, Yamakawa M, Mitake T, <u>Kudo M</u> , Fujimoto K	Mechanical model analysis for quantitative evaluation of liver fibrosis based on ultrasound tissue elasticity imaging.	Jpn J Appl Phys	51	07GF11-1-8	201 2
Tsuji Y, Watanabe T, <u>Kudo M</u> , Arai H, Strober W, Chiba T	Sensing of commensal organisms by the intracellular sensor NOD1 Mediates experimental pancreatitis.	Immunity	37	326-338	201 2
Sakamoto H, Kitano M, Kamata K, Miyata T, Kadosaka K, Imai H, Takeyama Y, <u>Kudo M</u>	Transcatheter endoscopy for pancreaticobiliary duct diseases (with videos).	Gastrointest Endosc	76	892-899	201 2
Takahashi K, Kashida H, <u>Kudo M</u>	Hepatic nodules associated with an inferior mesenteric arteriovenous malformation.	Internal Med	51	2753-2755	201 2
<u>Kudo M</u>	Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail?	Liver Cancer	1(2)	59-60	201 2
<u>Kudo M</u>	Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.	Liver Cancer	1(2)	62-70	201 2
Park AM, <u>Kudo M</u> , Hagiwara S, Tabuchi M, Watanabe T, Munakata H, Sakurai T	p38MAPK suppresses chronic pancreatitis by regulating HSP27 and BAD expression.	Free Radical Bio Med	52	2284-2291	201 2
Sakurai T, Kashida H, <u>Kudo M</u>	Case of Peutz-Jeghers syndrome with depressed-type early duodenal carcinoma.	Digest Endosc	24	489	201 2
<u>Kudo M</u>	Preface.	Digest Dis	30	539-540	201

					2
Hagiwara S, Sakurai T, Nishina S, Tanaka K, Ikeda M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Takita M, Nagai T, Hayaishi S, Arizumi T, Park AM, Munakata H, Nishida N, <u>Kudo M</u>	Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers.	Digest Dis	30	541-546	201 2
Nishida N, Arizumi T, Hayaishi S, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Ikai I, <u>Kudo M</u>	Gender differences in the livers of patients with hepatocellular carcinoma and chronic hepatitis C infection.	Digest Dis	30	547-553	201 2
Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Inao M, Tanaka A, Kaito M, Imazaki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsuhashi H, Izumi N, <u>Kudo M</u> , for RETRY study group	Retreatment with peginterferon alfa-2a plus ribavirin in patients who failed previous peginterferon alfa-2b plus ribavirin combination therapy.	Digest Dis	30	554-560	201 2
Hagiwara S, Sakurai T, Takita M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Nagai T, Hayaishi S, Arizumi T, Nishida N, <u>Kudo M</u>	Risk of HCC development in cases of hepatitis C treated by long-term, low-dose PEG-IFN α 2a.	Digest Dis	30	561-567	201 2
Kobayashi S, Kim SR, Imoto S, Ando K, Hirakawa M, Saito J, Fukuda K, Otono Y, Sakaki M, Tsuchida S, Kim SK, Hayashi Y, Nakano M, <u>Kudo M</u>	Histopathological diagnosis of early HCC through biopsy -efficacy of victoria blue and cytokeratin 7 staining-.	Digest Dis	30	574-579	201 2
Tsuchida S, Fukumoto T, Toyokawa A, Awazu M, Kusunoki N, Kido M, Takahashi M, Tanaka M, Kuramitsu K, Kim SR, <u>Kudo M</u> , Ku Y	Novel non-trocar technique for laparoscopic radiofrequency ablation.	Digest Dis	30	588-591	201 2
Minami Y, <u>Kudo M</u>	Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage.	Digest Dis	30	592-597	201 2
<u>Kudo M</u> , Ueshima K, Arizumi T	Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single center experience.	Digest Dis	30	609-616	201 2
Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, Imai Y, <u>Kudo M</u> , Murakami T	Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging.	Eur J Radiol	81	1460-1464	201 2
Nishida N, <u>Kudo M</u> , Nagasaka T, Ikai I, Goel A	Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma.	Hepatology	56	994-1003	201 2

Kitano M, Sakamoto H, <u>Kudo M</u>	Endoscopic ultrasound: contrast enhancement.	Gastrointest Endosc Clin N Am	22	349-358	2012
<u>Kudo M</u>	Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma.	World J Gastroenterol	18	6005-6017	2012
Inoue T, Kitai S, Hayaishi S, <u>Kudo M</u>	Septicemia due to vibrio cholerae serogroup non-O1/non-O139 strain in a cirrhotic patient.	Clin J Gastroenterol	5	383-387	2012
<u>Kudo M</u>	Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance.	Liver Cancer	1(3)	141-143	2012
Okusaka T, Kasugai H, Ishii H, <u>Kudo M</u> , Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T, Sakata K	A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.	Invest New Drug	30	2015-2025	2012
Hagiwara S, <u>Kudo M</u> , Chung H, Ueshima K, Inoue T, Haji S, Watanabe T, Park AM, Munakata H, Sakurai T	Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma.	Hepatol Res	42	394-400	2012
Sakurai T, <u>Kudo M</u> , Umemura A, He G, Elsharkawy AM, Seki E, Karin M	p38 α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.	Cancer Res	73	215-224	2012
<u>Kudo M</u>	Targeted therapy for liver cancer: updated review in 2012.	Curr Cancer Drug Tar	12	1062-1072	2012
Kaneko S, Furuse J, <u>Kudo M</u> , Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y	Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update.	Hepatol Res	42	523-542	2012
Inoue T, <u>Kudo M</u> , Komuta M, Hayaishi S, Ueda T, Takita M, Kitai S, Hatanaka K, Yada N, Hagiwara S, Chung H, Sakurai T, Ueshima K, Sakamoto M, Maenishi O, Hyodo T, Okada M, Kumano S, Murakami T	Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and Dysplastic nodule and comparison of detection sensitivity versus MDCT.	J Gastroenterol	47	1036-1047	2012
Nagai T, Arai T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H,	Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.	Mol Cancer Ther	10	169-177	2011

Fujita Y, Matsumoto K, Saijo N, <u>Kudo M</u> , Nishio K					
<u>Kudo M</u> , Hatanaka K, Kumada T, Toyoda H, Tada T	Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma.	Am J Gastroenterol	106	368-370	2011
Kudo K, Arao T, Tanaka K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, Velasco M, Fujita Y, Saijo N, <u>Kudo M</u> , Nishio K	Antitumor activity of BIBF 1120, a vascular endothelial growth factor-2 inhibitor and use of VEGFR2+pTYR+leucocyte as a pharmacodynamic biomarker.	Clin Cancer Res	17	1373-1381	2011
Hagiwara S, <u>Kudo M</u> , Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park AM, Munakata H	The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+pegylated interferon α -2b therapy against advanced hepatocellular carcinoma.	J Gastroenterol	46	212-221	2011
Sakamoto H, Kitano M, Matsui S, Kamata K, Komaki T, Imai H, Dote K, <u>Kudo M</u>	Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS.	Gastrointest Endosc	73	227-237	2011
Kagawa Y, Okada M, Kumano S, Katsube T, Imaoka I, Tanigawa N, Ishii K, <u>Kudo M</u> , Murakami T	Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR.	J Magn Reson Imaging	33	864-872	2011
Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokmi M, <u>Kudo M</u>	Management of hepatitis B: Consensus of Japan Society of Hepatology 2009.	Hepatol Res	41	1-21	2011
Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, <u>Kudo M</u> , Kitagaki H, Murakami T	Estimation of liver function using T1 mapping onGd-EOB-DTPA-enhanced magnetic resonance imaging.	Invest Radiol	46	277-283	2011
<u>Kudo M</u> , Yamao K, Shimosegawa T	The prognosis of patients with pancreatic cancer is extremely poor. Prefece.	Pancreatology	11	1-2	2011
Sakurai T, <u>Kudo M</u> , Fukuta N, Nakatani T, Kimura M, Park AM, Munakata H	Involvement of angiotensin II and reactive oxygen species in pancreatic fibrosis.	Pancreatology	11	7-13	2011
Kitano M, <u>Kudo M</u> , Sakamoto H, Komaki T	Endoscopic ultrasonography and contrast-enhanced endoscopic.	Pancreatology	11	28-33	2011
Komaki T, Kitano M, Sakamoto H, <u>Kudo M</u>	Endoscopic ultrasonography-guided biliary drainage: evaluation of a choledochoduodenostomy technique.	Pancreatology	11	47-51	2011
Sakamoto H, Kitano M, Komaki T, Imai H, Kamata K, <u>Kudo M</u>	Endoscopic ultrasound-guided neurolysis in pancreatic cancer.	Pancreatology	11	52-58	2011
Minami Y, <u>Kudo M</u>	Radiofrequency ablation of hepatocellular carcinoma: A literature review.	Int J Hepatol	2011	9pages (104685)	2011
Eguchi S, Kanematsu T, Arii S, Omata M, <u>Kudo M</u> , Sakamoto M, Takayasu K, Makuuchi	Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma.	Brit J Surg	98	552-557	2011

M, Matsuyama Y, Monden M, for the Liver Cancer Study Group of Japan					
Kitano M, Sakamoto H, Komaki T, <u>Kudo M</u>	New techniques and future perspective of EUS for the differential diagnosis of pancreatic malignancies; Contrast harmonic imaging.	Digest Endosc	23	46-50	201 1
<u>Kudo M</u>	Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.	Digest Dis	29	273-277	201 1
<u>Kudo M</u>	Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.	Digest Dis	29	289-302	201 1
<u>Kudo M</u>	mTOR inhibitor for the treatment of hepatocellular carcinoma.	Digest Dis	29	310-315	201 1
<u>Kudo M</u>	Future treatment option for hepatocellular carcinoma: a focus on brivanib.	Digest Dis	29	316-320	201 1
Ueshima K, <u>Kudo M</u> , Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T:	Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of Sorafenib for hepatocellular carcinoma.	Digest Dis	29	321-325	201 1
Hayaishi S, Chung H, <u>Kudo M</u> , Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K	Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis.	Digest Dis	29	326-332	201 1
<u>Kudo M</u> , Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M	Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guideline proposed by the Japan Society of Hepatology (JSH) 2010 updated version.	Digest Dis	29	339-364	201 1
Yoshida H, Shiratori Y, <u>Kudo M</u> , Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, Kawabe T, Kawazoe S, Kobashi H, Kasugai H, Osaki Y, Araki Y, Izumi N, Oka H, Tsuiji K, Toyota J, Seki T, Osawa T, Masaki N, Ichinose M, Seike M, Ishikawa A, Ueno Y, Tagawa K, Kuromatsu R, Sakisaka S, Ikeda H, Kuroda H, Hokuryu H, Yamashita T, Sakaida I, Katamoto T, Kikuchi K, Nomoto M, Omata M	Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.	Hepatology	54	532-540	201 1
Chung H, Watanabe T, <u>Kudo M</u> , Chiba T	Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection.	J Viral Hepat	18	e561-567	201 1

Kashida H, Ikehara N, Hamatani S, Kudo SE, <u>Kudo M</u>	Endoscopic characteristics of colorectal serrated lesions.	Hepato gastroenterology	58	1163-1167	201 1
<u>Kudo M</u> , Imanaka K, Chiba N, Nakachi K, Tak WT, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K	Phase III study of Sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.	Eur J Cancer	47	2117-2127	201 1
Llovet JM, Paradis V, <u>Kudo M</u> , Zucman-Rossi J	Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma.	Liver Transplant	17	S67-71	201 1
<u>Kudo M</u>	Tailor-made therapy for viral hepatitis: Recent advances.	Digestion	84	1-4	201 1
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, Hotta H, Maekawa Y, Hayashi Y, <u>Kudo M</u>	Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.	Digestion	84	5-9	201 1
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasaegawa Y, Fujinami A, Ohta M, Ei-Shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Kasugai H, Hotta H, <u>Kudo M</u>	ouble-filtration plasmapheresis plus interferon-β for HCV-1b patients with non-sustained virological response to previous combination therapy.	Digestion	84	10-16	201 1
Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y, <u>Kudo M</u>	Clinical characteristics of non-B non-C hepatocellular carcinoma: A single-center retrospective study.	Digestion	84	43-49	201 1
Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, <u>Kudo M</u>	Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.	Digestion	84	56-61	201 1
<u>Kudo M</u>	Hepatocellular carcinoma in 2011 and beyond: From the pathogenesis to molecular targeted therapy.	Oncology	81	1-10	201 1
Sakurai T, <u>Kudo M</u>	Signaling pathways governing tumor angiogenesis.	Oncology	81	24-29	201 1

Sakurai T, <u>Kudo M</u> , Itoh K, Ryu U, Higashitsuji H, Fujita J	Adriamycin enhances proteasome-mediated generation of the proapoptotic processed form of MAGE-A4 in hepatoma cells.	Oncology	81	30-35	201 1
<u>Kudo M</u>	Adjuvant therapy after curative treatment for hepatocellular carcinoma.	Oncology	81	50-55	201 1
Alaboudy A, Inoue T, Hatanak K, Chung H, Hyodo T, Kumano S, Murakami T, Moustafa EFA, <u>Kudo M</u>	Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.	Oncology	81	66-72	201 1
<u>Kudo M</u>	Diagnostic imaging of hepatocellular carcinoma: Recent progress.	Oncology	81	73-85	201 1
Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A, Saito S, Kita R, Kimura T, Osaki Y, <u>Kudo M</u>	Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with Sorafenib: A case report.	Oncology	81	152-157	201 1
Han KH, <u>Kudo M</u> , Ye SL, Choi JY, Poon RTP, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL	Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.	Oncology	81	158-164	201 1
Kim SR, Yang J, <u>Kudo M</u> , Hino O	Recent advances in the management of chronic hepatitis B.	Hepat Mon	11	601-611	201 1
Minami Y, <u>Kudo M</u>	Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma.	World J Gastroenterol	17	4952-4959	201 1
Higashi T, Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, <u>Kudo M</u> , Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Sobue T	the Liver Cancer Study Group of Japan: Demonstration of quality of care measurement using the Japanese liver cancer registry.	Hepatol Res	41	1208-1215	201 1
Suzuki H, Murata K, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, <u>Kudo M</u> , Mizokami M, Sakamoto A	Phenotype-dependent production of des- γ -carboxy prothrombin in hepatocellular carcinoma.	J Gastroenterol	46	1219-1229	201 1
Bridges JF, Joy SM, Gallego G, <u>Kudo M</u> , Ye SL, Han KH, Cheng AL, Blauvelt BM	Needs for hepatocellular carcinoma control policy in the Asia-pacific region.	Asian Pac J Cancer Prev	12	2585-91	201 1
Bridges JF, Gallego G, <u>Kudo M</u> , Okita K, Han KH, Ye SL, Blauvelt BM	Identifying and prioritizing strategies for comprehensive liver cancer control in Asia.	BMC Health Serv Res	Nov	298 (12p)	201 1
Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Nozaki Y, Nagata N, <u>Kikuchi Y</u> , Yanase M, Oka S.	Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection.	PLOS ONE	Volume 9	e87596	201 4

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, <u>Sakamoto M</u> , Maekawa S, Tokunaga K, Mizokami M, Izumi N.	Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C	J Med Virol	85 (3)	449-458	2013
Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Yamashita A, Moriishi K, Enomoto N.	Deep-Sequencing Analysis of the Association between the Quasispecies Nature of the Hepatitis C Virus Core Region and Disease Progression	J. Virol.	87	12541-12551	2013
Shindo H , Maekawa S, Komase K, Miura M, Sueki K, Komatsu K, Shindo K, Amemiya F, Nakayama T, Inoue T, <u>Sakamoto M</u> , Yamashita A, Moriishi K, Enomoto N	IL28B(IFN-λ3)and IFN-α synergistically inhibit HCV replication.	J Viral hepatitis	20(4)	281-289	2013
Kurosaki M, Hiramatsu N, <u>Sakamoto M</u> , Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Sugauchi F, Sakamoto N, Yatsuhashi H, Izumi N	Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.	Antiviral Therapy	17	35-43	2012
Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F, Nakayama Y, Kitamura T, Uetake T, Inoue T, <u>Sakamoto M</u> , Okada S, Enomoto N	Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C.	Hepatol Int	6	386-396	2012
Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Okada S, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.	Hepatol Int	6	386-396	2012
Osada M, Kaneko M, <u>Sakamoto M</u> , Endoh M, Takigawa K, Inoue-Suzuki K, Inoue O, Satoh K, Enomoto N, Yatomi Y, Ozaki Y	Causes of thrombocytopenia in chronic hepatitis C viral infection.	Clinical and Applied Thrombosis / Hemostasis	18	272-280	2012
Kurosaki M, Hiramatsu N, <u>Sakamoto M</u> , Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Izumi N	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.	J Hepatol	56 (3)	602-608	2012

Maekawa S, <u>Sakamoto M</u> (equally contributed), Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A, Ohmori T, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N	Comprehensive analysis for viral elements and IL28B polymorphisms in response to peginterferon plus ribavirin therapy in HCV-1b infection.	Hepatology	56	1611-1621	2012
Sueki R, Maekawa S, Miura M, Kadokura M, Komase K, Shindo H, Kanayama A, Ohmori T, Shindo K, Amemiya F, Nakayama Y, Uetake T, Inoue T, <u>Sakamoto M</u> , Enomoto N	Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection.	J Med Virol	84	1360-1368	2012
Komase K, Maekawa S, Miura M, Miura M, Sueki R, Kadokura M, Shindo H, Shido K, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Yamashita A, Moriishi K, Enomoto N.	The serum RANTES level influences the response to pegylated-interferon and ribavirin therapy in chronic hepatitis C.	Hepatology Research	43	865-875	2012
Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, <u>Sakamoto M</u> , Nakagawa M, Sakamoto N, Watanabe M, Enomoto N.	Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy.	Plos One	6(9)	e24514	2011
Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Sugauchi F, Tamori A, Matsuura K, Izumi N.	Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: Decision-tree analysis.	J Gastroenterol	46	1111-1119	2011
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugauchi M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, <u>Sakamoto M</u> , Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	54	439-448	2011
Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, <u>Sakamoto M</u> , Nakagawa M, Sakamoto N, Watanabe M, Enomoto N	Analysis of the complete open reading frame of hepatitis C virus genotype 2a infection reveals critical site influencing the response to peginterferon and ribavirin therapy.	Hepatol Int	5(3)	789-799	2011
Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N	Sequences in the Interferin Sensitivity Determining Region and Core Region of Hepatitis C Virus Impact Pretreatment Prediction of Response to Peg-interferon Plus Ribavirin: Data Mining Analysis.	J Med Virol	83	445-452	2011

Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Hiramatsu N, Sugauchi F, Yatsunami H, Izumi N.	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.	J Gastroenterol	46	401-409,	2011
<u>坂本穰</u> 、 <u>榎本信幸</u>	C型肝炎治療における宿主因子とウイルス因子 実地診療での臨床応用のすすめかた	Medical Practice	30 (2)	323-328	2013
<u>坂本穰</u> 、 <u>榎本信幸</u>	C型肝炎硬変における抗ウイルス療法	Modern physician	33 (4)	454-458	2013
<u>坂本穰</u> 、 <u>榎本信幸</u>	ウイルス変異と宿主ゲノムからみたインターフェロン療法の治療成績と発癌リスクを考慮した新規治療への展望	消化器内科	56 (4)	437-442	2013
<u>坂本穰</u> 、 <u>榎本信幸</u>	発癌リスクと治療反応性を考慮したC型肝炎の最新治療	消化器内科	57 (3)	379-384	2013
<u>坂本穰</u> 、 <u>榎本信幸</u>	C型肝炎診療 up-to-date、発癌リスクと新規治療法	診断と治療	101 (9)	1277-1282	2013
<u>坂本穰</u> 、 <u>榎本信幸</u>	C型肝炎の自然経過と発癌リスク	成人病と生活習慣病	43 (11)	1310-1315	2013
<u>坂本穰</u> 、 <u>榎本信幸</u>	C型肝炎ウイルスと治療	HIV感染症とAIDSの治療	4 (2)	55-59	2013
<u>坂本穰</u> 、 <u>榎本信幸</u>	プロテアーゼ阻害剤に対する耐性変異と意義	肝胆膵	67 (6)	893-898	2013
<u>坂本穰</u>	B型肝炎のインターフェロン治療：sequential therapyを含めて	Phama Medica	31 (12)	49-52	2013
<u>坂本穰</u> 、 <u>榎本信幸</u>	C型肝炎と肝癌 - 発癌リスクとウイルス排除の可能性、特集肝癌診療の最前線 - 知っておきたい診断・治療の新情報、	内科	109 (3)	420-424	2012
<u>坂本穰</u> 、 <u>榎本信幸</u>	抗HCV薬、特集：抗ウイルス薬	日本臨床	70 (4)	614-619	2012
<u>坂本穰</u> 、 <u>榎本信幸</u>	ウイルス変異と宿主ゲノム解析からみたPEG-IFN+RBV療法とProtease阻害剤の適応	消化器内科	54 (4)	454-458	2012
<u>坂本穰</u> 、 <u>榎本信幸</u>	C型肝炎の個別化治療 - 肝発がんの危険性とウイルス排除の可能性を考慮して -	Medical Practuce	29 (6)	1048-1049	2012
<u>坂本穰</u> 、 <u>榎本信幸</u>	ペグインターフェロン+リバビリン+テラプレビル併用療法 - 宿主・ウイルス因子の解析からみた最適な治療 -	消化器の臨床	15 (3)	249-256	2012
<u>坂本穰</u> 、 <u>榎本信幸</u>	C型肝炎のウイルス変異と治療効果	総合臨床	60 (1)	19-25	2011
<u>坂本穰</u> 、 <u>榎本信幸</u>	ウイルス変異からみたPEG-IFN+RBV療法の治療効果予測	肝胆膵	62 (2)	307-313	2011
<u>坂本穰</u> 、 <u>榎本信幸</u>	肝炎診療に必要な遺伝子検査。C型肝炎の遺伝子解析と診療への応用	Medical Practice	28 (8)	1383-1388	2011
Shirasaki T, Honda M, <u>Shimakami T</u> , Horii R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S, Yi M, Lemon SM, Kaneko S.	MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.	J Virol	87	5720-86	2013
Spaniel C, Honda M, Selitsky SR, Yamane D, <u>Shimakami T</u> , Kaneko S, Lanford RE, Lemon SM.	microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection.	PLoS One	8	e76867	2013
Honda M, Shirasaki T, <u>Shimakami T</u> , Sakai A, Horii R, Arai K, Yamashita T, Sakai Y, Yamashita T, Okada H, Murai K, Nakamura M, Mizukoshi E, Kaneko S.	Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin 28B genotypes.	Hepatology	in press	in press	2013

Posuwan N, Payungporn S, Tangkijvanich P, Ogawa S, Murakami S, Iijima S, Matsuura K, Shinkai N, <u>Watanabe T</u> , Poovorawan Y, Tanaka Y.	Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in thai population.	PLoS One	9(1)	e86007	201 4
Matsuura K, <u>Watanabe T</u> , and Tanaka Y.	Role of IL28B for chronic hepatitis C treatment toward personalized medicine.	J Gastroenterol Hepatol.	29(2)	241-9	201 4
Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, <u>Watanabe T</u> , Tanaka Y.	Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.	Liver Int.	in press	doi: 10.1111/liv.12321. PMID: 24102823	201 3
<u>Watanabe T</u> , Inoue T, Tanoue Y, Maekawa H, Hamada-Tsutsumi S, Yoshihara S, Tanaka Y.	Hepatitis C Virus Genotype 2 May Not Be Detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0.	J Clin Microbiol.	51(12)	4275-4276	201 3
Shinkai N, Matsuura K, Sugauchi F, <u>Watanabe T</u> , Murakami S, Iio E, Ogawa S, Nojiri S, Joh T, Tanaka Y.	Application of a Newly Developed High-Sensitivity HBsAg Chemiluminescent Enzyme Immunoassay for Hepatitis B Patients with HBsAg Seroclearance.	J Clin Microbiol	51	3484-3491	201 3
Wong DK, <u>Watanabe T</u> , Tanaka Y, Seto WK, Lee CK, Fung J, Lin CK, Huang FY, Lai CL, Yuen MF.	Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese.	PLoS One	8	e66920	201 3
Arata S, Nozaki A, Takizawa K, Kondo M, Morimoto M, Numata K, Hayashi S, <u>Watanabe T</u> , Tanaka Y, Tanaka K.	Hepatic failure in pregnancy successfully treated by online hemodiafiltration: Chronic hepatitis B virus infection without viral genome mutation.	Hepatol Res	43(12)	1356-60	201 3
Sakamoto T, Tanaka Y, <u>Watanabe T</u> , and Mizokami M.	Mechanism of the dependence of hepatitis B virus genotype G on co-infection with other genotypes for viral replication.	J Viral Hepat	20(4)	e27-36	201 3
<u>Watanabe T</u> , and Tanaka Y.	Reactivation of hepatitis viruses following immunomodulation systemic chemotherapy.	Hepatol Res.	43(2)	113-21	201 3
<u>Watanabe T</u> , Sugauchi F, Tanaka Y, and Mizokami M.	Hepatitis C virus kinetics by administration of pegylated interferon- α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.	GUT	62(9)	1340-6	201 3
1) Sandalova E, Laccabue D, Boni C., <u>Watanabe T</u> , Tan A, Zong ZH, Ferrari C, Bertoletti A.	Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells.	Gastroenterology	143(1)	78-87	201 2
Kani S, Tanaka Y, Matsuura K, <u>Watanabe T</u> , Yatsunami H, Orito E, Inose K, Motojuku N, Wakimoto Y, and Mizokami M.	Development of new IL28B genotyping method using Invader Plus assay.	Microbiol Immunol.	56(5)	318-23	201 2
吉岡健太郎、橋本千樹、 川部直人、原田雅生、西 川徹、市野直浩、刑部恵	FibroScan を用いた治療後肝硬度変化の測定	肝胆膵	67(6)	1059-1064	201 3

介					
K. Hayashi, Y. Katano, H. Masuda, Y. Ishizu, T. Kuzuya, T. Honda, M. Ishigami, A. Itoh, Y. Hirooka, I. Nakano, T. Ishikawa, F. Urano, K. Yoshioka, H. Toyoda, T. Kumada and H. Goto	Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B	Hepatol Res	43(6)	580-8	201 3
<u>K. Yoshioka</u>	What is the benefit of computer-assisted image analysis of liver fibrosis area?	J Gastroenterol	48(8)	996-7	201 3
<u>K. Yoshioka</u>	How to adjust the inflammation-induced overestimation of liver fibrosis using transient elastography?	Hepatol Res	43(2)	182-4	201 3
<u>Yoshioka K</u> , Hashimoto S	Can non-invasive assessment of liver fibrosis replace liver biopsy?	Hepatol Res	42(3)	233-40	201 2
Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami Nakano M, Urano F, <u>Yoshioka K</u> , Toyoda H, Kumada T, Goto H	Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin	J Med Virol	84(3)	438-44	201 2
中野若香菜、池夏希、石渡朝子、伊藤広子、菱田麻由佳、伊藤志歩、花下順子、池田綾子、原田雅生、川部直人、橋本千樹、 <u>吉岡健太郎</u>	C型肝硬変患者に対する分岐鎖アミノ酸製剤による late evening snack を含む栄養管理の長期効果	栄養評価と治療	29(4)	357-363	201 2
<u>吉岡健太郎</u> 、橋本千樹、川部直人、原田雅生、西川徹、市野直浩、刑部恵介	Fibroscan による線維化診断と発癌予測	肝胆膵	65(6)	1029-1034	201 2
川部直人、橋本千樹、原田雅生、有馬裕子、西川徹、 <u>吉岡健太郎</u>	C型慢性肝炎における肝線維化推定と抗ウイルス治療	臨床消化器内科	27(11)	1467-1474	201 2
Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Arima Y, Suzuki K, <u>Yoshioka K</u>	Reduction of liver stiffness by antiviral therapy in chronic hepatitis B	J Gastroenterol	46(11)	1324-34	201 1
Chayama K, Hayes CN, <u>Yoshioka K</u> , Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H	Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C	J Gastroenterol	46(4):	545-555	201 1
Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, <u>Yoshioka K</u> , Toyoda H, Kumada T, Goto H	Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.	J Viral Hepat	18(4)	280-286	201 1

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, <u>Yoshioka K</u> , Toyoda H, Kumada T, Goto H.	Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy	Liver Int	31(9)	1359-65.	2011
Harata M, Hashimoto S, Kawabe N, Nitta Y, Murao M, Nakano T, Arima Y, Shimazaki H, Ishikawa T, Okumura A, Ichino N, Osakabe K, Nishikawa T, <u>Yoshioka K</u> .	Liver stiffness in extrahepatic cholestasis correlates positively with bilirubin and negatively with alanine aminotransferase	Hepatol Res	41(5)	423-429	2011
矢野元義、 <u>吉岡健太郎</u> 、林久男	C型慢性肝炎に対する治療学の進歩 C型肝炎に対するインターフェロン以外の治療法 瀉血療法	日本臨床	64 (4)	262-266	2011
Matsunaga M, Isowa T, Yamakawa K, Tsuboi H, Kawanishi Y, Kaneko H, Kasugai K, <u>Yoneda M</u> , Ohira H	Association between perceived happiness levels and peripheral circulating pro-inflammatory cytokine levels in middle-aged adults in Japan.	Neuro Endocrinol Lett.	32(4)	458-63	2011
<u>Nakao H</u> , <u>Yoneda M</u>	Liver stiffness measurement using transient elastography and hepatocellular carcinoma.	Hepatol Res.	41(10)	921-4	2011
Kono T, Kashiwade Y, Asama T, Chisato N, Ebisawa Y, <u>Yoneda M</u> , Kasai S.	Preventive effect of urinary trypsin inhibitor on the development of liver fibrosis in mice.	Exp Biol Med	236(11)	1314-21	2011
Iida A, Konagaya T, Kaneko H, Funaki Y, Kanazawa T, Tokudome K, Hijikata Y, Masui R, Ogasawara N, Sasaki M, Yoneda M, Kasugai K.	Usefulness of a slow nutrient drinking test for evaluating gastric perception and accommodation.	Digestion.	84(4)	253-60	2011
Qin Y, Zhang J, Garcia T, <u>Ito K</u> , Gutelius D, Li J, Wands J, Tong S.	Improved method for rapid and efficient determination of genome replication and protein expression of clinical hepatitis B virus isolates.	J Clin Microbiol	49(4)	1226-33	2011
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, <u>Ito K</u> , Masaki N, Tokunaga K, Izumi N, Mizokami M.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	54(3)	439-48	2011
Kuno A, Ikehara Y, Tanaka Y, Angata T, Unno S, Sogabe M, Ozaki H, <u>Ito K</u> , Hirabayashi J, Mizokami M, Narimatsu H.	Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray.	Clin Chem	57(1)	48-56	2011
Furui Y, Hoshi Y, Murata K, <u>Ito K</u> , Suzuki K, Uchida S, Satake M, Mizokami M, Tadokoro K.	Prevalence of amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors.	J Med Virol	83(11)	1924-9	2011
Sugiyama M, Inui A, Shin-I T, Komatsu H, Mukaide M, Masaki N, Murata K, <u>Ito K</u> , Nakanishi	Easy-to-use phylogenetic analysis system for hepatitis B virus infection.	Hepatol Res	41(10)	936-45	2011

M, Fujisawa T, Mizokami M.					
Kuno A, Ikehara Y, Tanaka Y, Saito K, Ito K, Tsuruno C, Nagai S, Takahama Y, Mizokami M, Hirabayashi J, Narimatsu H.	LecT-Hepa: A triplex lectin-antibody sandwich immunoassay for estimating the progression dynamics of liver fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine.	Clin Chim Acta	412(19-20)	1767-72	2011
<u>Ito K</u> , Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsuhashi H, Orito E, Kani S, Tanaka Y, Mizokami M.	The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.	J Clin Microbiol	49(5)	1853-60	2011
Kono T, Asama T, Chisato N, Ebisawa Y, Okayama T, Imai K, Karasaki H, Furukawa H, <u>Yoneda M</u> .	Polaprezinc prevents ongoing thioacetamide-induced liver fibrosis in rats.	Life Sci.	90(3-4)	122-30	2012
Tamano M, Kojima K, Akima T, Murohisa T, Hashimoto T, Uetake C, Sugaya T, Nakano M, Hiraishi H, <u>Yoneda M</u>	The usefulness of measuring liver stiffness by transient elastography for assessing hepatic fibrosis in patients with various chronic liver diseases.	<u>Hepatogastroenterology</u>	59(115)	826-30	2012
Sawai H, Nishida N, Mbarek H, Matsuda K, Mawatari Y, Yamaoka M, Hige S, Kang JH, Abe K, Mochida S, Watanabe M, Kurosaki M, Asahina Y, Izumi N, Honda M, Kaneko S, Tanaka E, Matsuura K, Itoh Y, Mita E, Korenaga M, Hino K, Murawaki Y, Hiasa Y, Ide T, <u>Ito K</u> , Sugiyama M, Ahn SH, Han KH, Park JY, Yuen MF, Nakamura Y, Tanaka Y, Mizokami M, Tokunaga K.	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations.	BMC Med Genet		13 47	2012
Sugiyama M, Kimura T, Naito S, Mukaide M, Shinauchi T, Ueno M, <u>Ito K</u> , Murata K, Mizokami M.	Development of specific and quantitative real-time detection PCR and immunoassays for λ 3-interferon.	Hepatol Res	42(11)	1089-99	2012
Nomura H, Miyagi Y, Tanimoto H, Yamashita N, <u>Ito K</u> , Masaki N, Mizokami M.	Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.	J Gastroenterol Hepatol	27(9)	1461-6	2012
Saito H, <u>Ito K</u> , Sugiyama M, Matsui T, Aoki Y, Imamura M, Murata K, Masaki N, Nomura H, Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S.	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients.	Hepatol Res	42(10)	958-965	2012

Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K, Masaki N, Tanaka Y, Hige S, Izumi N, Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M.	LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients.	Hepatology	56(4)	1448-56	2012
Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K, Nakao H, Haneda M, Yoneda M.	<u>Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.</u>	J Gastroenterol	48(4)	491-503	2013
Yotsuyanagi H, Ito K, Yamada N, Takahashi H, Okuse C, Yasuda K, Suzuki M, Moriya K, Mizokami M, Miyakawa Y, Koike K.	High Levels of Hepatitis B Virus After the Onset of Disease Lead to Chronic Infection in Patients With Acute Hepatitis B.	Clin Infect Dis	57(7)	935-42	2013
Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H.	A Serum A"sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.	Sci Rep	3	1065	2013
Miyagi Y, Nomura H, Yamashita N, Tanimoto H, Ito K, Masaki N, Mizokami M, Shibuya T.	Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.	J Infect Chemother	19(1)	63-69	2013
Ito K, Yotsuyanagi H, Yatsushashi H, Krino Y, Takikawa Y, Saito t, AraseY, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Meshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group.	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.	Hepatology	59(1)	89-97	2014
Murata K, Sugiyama M, Kimura T, Yoshio S, Kanto T, Kirikae I, Saito H, Aoki Y, Hiramane S, Matsui T, Ito K, Korenaga M, Imamura M, Masaki N, Mizokami M.	Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients.	J Gastroenterol	49(1)	126-37	2014
Yoneda M	Is the measurement of serum cytokeratin-18 useful for diagnosis or screening nonalcoholic steatohepatitis?	Hepatol Res (in press).			
Nakade Y, Yoneda M	Prognostic factors for Regression from impaired glucose tolerance to Normal Glucose Regulation in Japanese patients with nonalcoholic fatty liver disease.	Intern Med (in press)			

Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, <u>Ishigami M</u> , Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.	Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B.	Hepatol Res	43	580-588	2013
Honda T, Katano Y, Kuzuya T, Hayashi K, <u>Ishigami M</u> , Itoh A, Hirooka Y, Nakano I, Ishikawa T, Toyoda H, Kumada T, Yamamoto K, Matsushita T, Kojima T, Takamatsu J, Goto H.	Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders.	J Med Virol	85	228-234	2013
Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, <u>Ishigami M</u> , Itoh A, Hirooka Y, Ishikawa T, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.	Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.	J Med Virol	84	438-444	2012
Ishizu Y, Katano Y, Honda T, Hayashi K, <u>Ishigami M</u> , Itoh A, Hirooka Y, Nakano I, Goto H.	Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.	J Gastroenterol Hepatol	27	1112-1116	2012
田中弘教, 飯島尋子	造影超音波検査 - 厚生労働省有井班の診断アルゴリズムを含めて - .	臨牀と研究	90	188-93	2013
飯島尋子	超音波造影剤による肝腫瘍診断	Mebio	30	39-45	2013
田中弘教, 池田直人, 岩田一也, 高嶋智之, 楊和典, 石井昭生, 坂井良行, 會澤信弘, 岩田恵典, 榎本平之, 齋藤正紀, 今西宏安, 西口修平, 飯島尋子	穿刺針ナビゲーションシステム VirtuTRAXTM 安全使用のための短縮クリップ法 .	肝臓	54	291-3	2013
田中弘教, <u>飯島尋子</u>	肝細胞がんの Vascular Invasion-画像診断から脈管浸潤の限界にせまる - .	肝胆膵	66	935-40	2013
Mitsunori Y, Tanaka S, Nakamura N, Ban D, Irie T, Noguchi N, Kudo A, <u>Iijima H</u> , Arii S.	Contrast-enhanced intraoperative ultrasound for hepatocellular carcinoma: high sensitivity of diagnosis and therapeutic impact.	J Hepatobiliary Pancreat Sci.	20	234-42	2013
Bota S, Sporea I, Peck-Radosavljevic M, Sirli R, Tanaka H, <u>Iijima H</u> , Saito H, Ebinuma H, Lupsor M, Badea R, Fierbinteanu-Braticevic	The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study.	Dig Liver Dis.		Epub ahead of print	2013

i C, Petrisor A, Friedrich-Rust M, Sarrazin C, Takahashi H, Ono N, Piscaglia F, Marinelli S, D'Onofrio M, Gallotti A, Salzl P, Popescu A, Danila M.					
Tamura Y, Suda T, Aarii S, Sata M, Moriyasu F, Imamura H, Kawasaki S, Izumi N, Takayama T, Kokudo N, Yamamoto M, <u>Iijima H</u> , Aoyagi Y.	Value of Highly Sensitive Fucosylated Fraction of Alpha-Fetoprotein for Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment.	Dig Dis Sci.	58	2406-12	2013
Enomoto H, Sakai Y, Aizawa N, Iwata Y, Tanaka H, Ikeda N, Kunihiro H, You K, Ishii A, Takashima T, Iwata K, Saito M, Imanishi H, <u>Iijima H</u> , Nishiguchi S.	Association of amino acid imbalance with the severity of liver fibrosis and esophageal varices.	Ann Hepatol.	12	471-8	2013
Tanaka H, <u>Iijima H</u> , Higashiura A, Yoh K, Ishii A, Takashima T, Sakai Y, Aizawa N, Iwata K, Ikeda N, Iwata Y, Enomoto H, Saito M, Imanishi H, Hirota S, Fujimoto J, Nishiguchi S.	New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography.	J Gastroenterol.		Epub ahead of print	2013
飯島尋子, 井倉技, 中山晴夫, 小林正宏, 熊田博光, 井廻道夫.	血清アルブミン濃度が軽度～中等度に低下した肝硬変患者の QOL に及ぼすリーバクト R 配合顆粒の影響.	Medicine and Drug Journal.	49	127-39	2013
Singh S, Eaton JE, Murad MH, Tanaka H, <u>Iijima H</u> , Talwalkar JA.	Accuracy of Spleen Stiffness Measurement in Detection of Esophageal Varices in Patients With Chronic Liver Disease: Systematic Review and Meta-analysis.	Clin Gastroenterol Hepatol.		Epub ahead of print	2013
Aizawa N, Enomoto H, Takashima T, Sakai Y, Iwata K, Ikeda N, Tanaka H, Iwata Y, Saito M, Imanishi H, <u>Iijima H</u> , Nishiguchi S.	Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.	J Gastroenterol.		Epub ahead of print	2013
Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, <u>Iijima H</u> , Ochi H, Hirooka M, Imai Y, Kudo M.	Hypovascular Hepatic Nodules Showing Hypointense on the Hepatobiliary-Phase Image of Gd-EOB-DTPA-Enhanced MRI to Develop a Hypervascular Hepatocellular Carcinoma: A Nationwide Retrospective Study on Their Natural Course and Risk Factors.	Dig Dis.	31	472-9	2013
Sakata K, Hara M, Terada T, Watanabe N, Takaya D, Yaguchi S, Matsumoto T,	CV NS3 protease enhances liver fibrosis via binding to and activating TGF- β type I receptor.	Sci Rep.	22	3243	2013

Matsuura T, Shirouzu M, Yokoyama S, Yamaguchi T, Miyazawa K, Aizaki H , Suzuki T, Wakita T, Imoto M, Kojima S.					
Nakajima S, Watashi K, Kamisuki S, Tsukuda S, Takemoto K, Matsuda M, Suzuki R, Aizaki H , Sugawara F, Wakita T.	Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives.	Biochem Biophys Res Commun.	440	515-20	2013
Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T, Suzuki R, Li J, Tong S, Tanaka Y, Murata K, Aizaki H , Wakita T.	Interleukin-1 and Tumor Necrosis Factor- α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID).	J Biol Chem.	288	31715-27	2013
Suzuki R, Matsuda M, Watashi K, Aizaki H , Matsuura Y, Wakita T, Suzuki T.	Signal peptidase complex subunit 1 participates in the assembly of hepatitis C virus through an interaction with E2 and NS2.	PLoS Pathog.	9	e1003589	2013
Matsumoto Y, Matsuura T, Aoyagi H, Matsuda M, Hmwe SS, Date T, Watanabe N, Watashi K, Suzuki R, Ichinose S, Wake K, Suzuki T, Miyamura T, Wakita T, Aizaki H .	Antiviral activity of glycyrrhizin against hepatitis C virus in vitro.	PLoS One.	18	e68992	2013
Akazawa D, Moriyama M, Yokokawa H, Omi N, Watanabe N, Date T, Morikawa K, Aizaki H , Ishii K, Kato T, Mochizuki H, Nakamura N, Wakita T.	Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.	Gastroenterology.	145	447-55	2013
Suzuki R, Ishikawa T, Konishi E, Matsuda M, Watashi K, Aizaki H , Takasaki T, Wakita T.	Production of single-round infectious chimeric flaviviruses with DNA-based Japanese encephalitis virus replicon.	J Gen Virol.	95	60-65	2014
Iwamoto M, Watashi K, Tsukuda S, Aly1 HH, Fukasawa M, Suzuki R, Aizaki H , Ito T, Koiwai O, Kusuhara H, Wakita T	Evaluation and Identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.	Biochem Biophys Res Commun.	443	808-13	2014
Helene Minyi Liu, Hideki Aizaki , Keigo Machida, J.-H. James Ou, Michael M. C. Lai	Hepatitis C Virus Translation Preferentially Depends on Active RNA Replication	PLoS One	7(8)	e43600	2012
Ryosuke Suzuki, Kenji Saito, Takanobu Kato, Masayuki Shirakura, Daisuke Akazawa, Koji Ishii, Hideki Aizaki , Yumi Kanegae,	Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection	Virology	432	29-38	2012

Yoshiharu Matsuura, Izumu Saito, Takaji Wakita, Tetsuro Suzuki					
Asako Murayama, Nao Sugiyama, Koichi Watashi, Takahiro Masaki, Ryosuke Suzuki, Hideki Aizaki , Toshiaki Mizuochi, Takaji Wakita, Takanobu Kato	Japanese Reference Panel of Blood Specimens for Evaluation of Hepatitis C Virus RNA and Core Antigen Quantitative Assays	Journal of Clinical Microbiology	50(6)	1943-1949	201 2
Tomomi Ando, Hiromi Imamura, Ryosuke Suzuki, Hideki Aizaki , Toshiki Watanabe, Takaji Wakita, Tetsuro Suzuki	Visualization and Measurement of ATP Levels in Living Cells Replicating Hepatitis C Virus Genome RNA	Pathogens	8(3)		201 2
Yamamoto M, Aizaki H , Fukasawa M, Teraoka T, Miyamura T, Wakita T, Suzuki T	The structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus.	J Gen.Virol.	92	Jul-82	201 1
Watanabe N, Aizaki H , Matsuura T, Kojima S, Wakita T, Suzuki T	Hepatitis C virus RNA replication in human stellate cells regulates gene expression of extracellular matrix-related molecules.	Biochem Biophys Res Commun.	407	135-40	201 1
Inoue Y, Aizaki H , Hara H, Matsuda M, Ando T, Shimoji T, Murakami K, Masaki T, Shoji I, Homma S, Matsuura Y, Miyamura T, Wakita T, Suzuki T	Chaperonin TRiC/CCT participates in replication of hepatitis C virus genome via interaction with the viral NS5B protein.	Virology	410	38-47	201 1